Targeting the WASF3 Regulatory Complex in Pancreatic Cancer Using Stapled Peptides

Taylor C Dill1, Elliot J Alger2, Sophia Gambale2

  • 1Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.

Biochemistry
|June 24, 2026
PubMed

Insights

A novel peptide, WAHM1, disrupts the WASF Regulatory Complex (WRC) in pancreatic cancer cells. This disruption suppresses tumor cell invasion and migration, offering a potential new therapeutic strategy.

Area of Science:

  • Cell Biology
  • Molecular Oncology
  • Biochemistry

Background:

  • Wiskott-Aldrich Syndrome Protein Family (WASF) members, including WASF3, are crucial for actin cytoskeletal remodeling.
  • Elevated WASF3 expression in pancreatic cancer correlates with poor prognosis, increased invasion, and metastasis.
  • The WASF Regulatory Complex (WRC) is a key regulator of WASF protein function.

Purpose of the Study:

  • To investigate if disrupting the WRC can inhibit WASF3-driven actin polymerization, cellular invasion, and motility in pancreatic cancer.
  • To identify specific molecular strategies targeting the WRC for therapeutic intervention in pancreatic cancer.

Main Methods:

  • Screening of constrained peptides designed to interfere with WRC protein-protein interactions.
  • Evaluation of peptide efficacy in suppressing pancreatic cancer cell lines (PANC-1, BxPC-3).
  • Assessment of peptide cellular permeability, target binding, and WRC protein level reduction.

Main Results:

  • A WASF3-derived peptide, WAHM1, effectively suppressed pancreatic cancer cell motility and invasion.
  • WAHM1 demonstrated cellular permeability and specific binding to WRC targets within pancreatic cancer cells.
  • Treatment with WAHM1 led to a reduction in WRC protein levels.

Conclusions:

  • Disruption of the WRC using the peptide WAHM1 is a viable strategy to inhibit pancreatic cancer cell invasion and migration.
  • WAHM1 shows promise as a potential therapeutic agent to downregulate WASF3-mediated processes in pancreatic cancer.
  • Targeting the WRC represents a novel approach for developing complementary therapies for pancreatic cancer.

Related Concept Videos